Protagonist Therapeutics (PTGX) News
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
143.73+3.82 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PTGX news summary
We found 3 recent headlines mentioning Protagonist Therapeutics (PTGX): 0 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, PTGX is up 2.73% at $143.73. The most recent story, "J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?", was published by Nasdaq on Sep 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Protagonist Therapeutics headlines
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.NasdaqJNJ, LLY, GILD, PTGX
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.Key PointsJ&J's portfolio primarily includes small biotech and medtech companies.NasdaqPTGX, JNJ, LAB, XNCR